Description
Encorafenib
Each capsule contains: Encorafenib … 75mg.
INDICATIONS
LuciEncor is a kinase inhibitor indicated, in combination with Binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
DOSAGE AND USE
• Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to the initiation of LuciEncor. • The recommended dose is 450 mg orally once daily in combination with Binimetinib. Take LuciEncor with or without food.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNINGS
Keep medicine out of reach of Children. Do not administer LuciEncor during Pregnancy and Lactation.
Reviews
There are no reviews yet.